首页 > 最新文献

Clinical and Experimental Neuroimmunology最新文献

英文 中文
Muscle magnetic resonance imaging findings in patients with idiopathic inflammatory myopathies 特发性炎性肌病患者的肌肉磁共振成像表现
Q4 Immunology and Microbiology Pub Date : 2025-01-29 DOI: 10.1111/cen3.12831
Tadanori Hamano, Tomoko Kamisawa, Sayaka Sanada, Kouji Hayashi

Background

Idiopathic inflammatory myopathies (IIMs) are disorders that cause chronic muscle inflammation and weakness due to an autoimmune pathogenesis. Dermatomyositis (DM) is a typical IIM disorder, along with others including antisynthetic syndrome (ASS), immune-mediated necrotizing myopathy (IMNM), overlap myositis, inclusion body myositis (IBM), and anti-mitochondrial M2 antibody-positive myositis (AMA-myositis). Noninvasive muscle magnetic resonance imaging (MRI) is useful for determining the distribution, nature, and extent of lesions in affected muscles. T1-weighted MRI is useful for observing morphological changes, including muscle atrophy. Short tau inversion recovery images or T2-weighted images are useful for detecting muscle inflammation and edema and are suitable for selecting optimal biopsy sites. Muscle MRI is also useful for follow-up studies.

Results

On muscle MRI, patients with DM show a symmetric pattern with prominent fasciitis. The MRI findings in ASS are similar to those in DM. In IMNM, MRI findings are asymmetric, present a rapid and severe course, and fasciitis is less prominent. In IBM, atrophy is more severe at presentation than in other IIMs, and fasciitis is absent. In AMA-myositis, fasciitis is severe and atrophy is mild.

Conclusion

Muscle MRI can help differentiate between IIMs along with using other laboratory findings, including myositis-specific antibodies.

特发性炎症性肌病(IIMs)是一种由自身免疫性发病机制引起的慢性肌肉炎症和无力的疾病。皮肌炎(DM)是一种典型的IIM疾病,其他疾病包括抗合成综合征(ASS)、免疫介导的坏死性肌病(IMNM)、重叠肌炎、包涵体肌炎(IBM)和抗线粒体M2抗体阳性肌炎(AMA-myositis)。无创肌肉磁共振成像(MRI)可用于确定受影响肌肉病变的分布、性质和程度。t1加权MRI可用于观察形态学变化,包括肌肉萎缩。短tau反转恢复图像或t2加权图像对检测肌肉炎症和水肿有用,适合选择最佳活检部位。肌肉MRI对后续研究也很有用。结果DM患者的肌肉MRI表现为对称型,筋膜炎突出。ASS的MRI表现与DM相似。IMNM的MRI表现不对称,病程迅速且严重,筋膜炎不太突出。在IBM中,萎缩在表现上比其他IIMs更严重,并且没有筋膜炎。在ama -肌炎中,筋膜炎是严重的,萎缩是轻微的。结论:肌肉MRI可以帮助区分IIMs以及其他实验室检查结果,包括肌炎特异性抗体。
{"title":"Muscle magnetic resonance imaging findings in patients with idiopathic inflammatory myopathies","authors":"Tadanori Hamano,&nbsp;Tomoko Kamisawa,&nbsp;Sayaka Sanada,&nbsp;Kouji Hayashi","doi":"10.1111/cen3.12831","DOIUrl":"https://doi.org/10.1111/cen3.12831","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Idiopathic inflammatory myopathies (IIMs) are disorders that cause chronic muscle inflammation and weakness due to an autoimmune pathogenesis. Dermatomyositis (DM) is a typical IIM disorder, along with others including antisynthetic syndrome (ASS), immune-mediated necrotizing myopathy (IMNM), overlap myositis, inclusion body myositis (IBM), and anti-mitochondrial M2 antibody-positive myositis (AMA-myositis). Noninvasive muscle magnetic resonance imaging (MRI) is useful for determining the distribution, nature, and extent of lesions in affected muscles. T<sub>1</sub>-weighted MRI is useful for observing morphological changes, including muscle atrophy. Short tau inversion recovery images or T<sub>2</sub>-weighted images are useful for detecting muscle inflammation and edema and are suitable for selecting optimal biopsy sites. Muscle MRI is also useful for follow-up studies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>On muscle MRI, patients with DM show a symmetric pattern with prominent fasciitis. The MRI findings in ASS are similar to those in DM. In IMNM, MRI findings are asymmetric, present a rapid and severe course, and fasciitis is less prominent. In IBM, atrophy is more severe at presentation than in other IIMs, and fasciitis is absent. In AMA-myositis, fasciitis is severe and atrophy is mild.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Muscle MRI can help differentiate between IIMs along with using other laboratory findings, including myositis-specific antibodies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10193,"journal":{"name":"Clinical and Experimental Neuroimmunology","volume":"16 1","pages":"72-83"},"PeriodicalIF":0.0,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cen3.12831","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143456106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Interferons in myositis: Pathogenesis and therapy 肌炎中的干扰素:发病机制和治疗
Q4 Immunology and Microbiology Pub Date : 2025-01-26 DOI: 10.1111/cen3.12827
Nozomu Tawara

Idiopathic inflammatory myopathies (IIMs), or myositis, are a heterogeneous group of autoimmune diseases affecting skeletal muscle and other organs. Recent research has revealed the important role of interferons (IFNs) in the pathogenesis of IIMs. This review summarizes the three types of IFNs and their functions in the immune system, focusing on their association with different IIM subtypes. Dermatomyositis (DM) is strongly associated with Type I IFNs. In contrast, inclusion body myositis (IBM), polymyositis with mitochondrial pathology (PM-mito), and anti-synthetase syndrome (ASyS) are predominantly associated with Type II IFN. This review explores the molecular mechanisms underlying these associations and their impact on muscle function. In addition, the potential of the IFN signaling pathway as a therapeutic target for IIMs will be discussed. Several clinical trials are currently underway or planned that target the IFN pathway using JAK inhibitors and monoclonal antibodies against Type I IFNs. JAK inhibitors have shown promise in treating DM, particularly in refractory cases. However, more research is needed to fully understand their efficacy and safety profiles in IIMs. The review concludes by highlighting the importance of ongoing research in this area and the potential for new targeted therapies in treating IIMs.

特发性炎症性肌病(IIMs)或肌炎是一种影响骨骼肌和其他器官的异质自身免疫性疾病。最近的研究揭示了干扰素(IFNs)在IIMs发病机制中的重要作用。本文综述了ifn的三种类型及其在免疫系统中的功能,重点介绍了它们与不同IIM亚型的关系。皮肌炎(DM)与I型ifn密切相关。相反,包涵体肌炎(IBM)、线粒体病理多发性肌炎(PM-mito)和抗合成酶综合征(ASyS)主要与II型IFN相关。这篇综述探讨了这些关联的分子机制及其对肌肉功能的影响。此外,将讨论IFN信号通路作为IIMs治疗靶点的潜力。目前正在进行或计划进行一些临床试验,使用JAK抑制剂和针对I型IFN的单克隆抗体靶向IFN通路。JAK抑制剂在治疗糖尿病,特别是难治性病例方面显示出前景。然而,需要更多的研究来充分了解它们在iim中的疗效和安全性。综述最后强调了该领域正在进行的研究的重要性以及治疗IIMs的新靶向疗法的潜力。
{"title":"Interferons in myositis: Pathogenesis and therapy","authors":"Nozomu Tawara","doi":"10.1111/cen3.12827","DOIUrl":"https://doi.org/10.1111/cen3.12827","url":null,"abstract":"<p>Idiopathic inflammatory myopathies (IIMs), or myositis, are a heterogeneous group of autoimmune diseases affecting skeletal muscle and other organs. Recent research has revealed the important role of interferons (IFNs) in the pathogenesis of IIMs. This review summarizes the three types of IFNs and their functions in the immune system, focusing on their association with different IIM subtypes. Dermatomyositis (DM) is strongly associated with Type I IFNs. In contrast, inclusion body myositis (IBM), polymyositis with mitochondrial pathology (PM-mito), and anti-synthetase syndrome (ASyS) are predominantly associated with Type II IFN. This review explores the molecular mechanisms underlying these associations and their impact on muscle function. In addition, the potential of the IFN signaling pathway as a therapeutic target for IIMs will be discussed. Several clinical trials are currently underway or planned that target the IFN pathway using JAK inhibitors and monoclonal antibodies against Type I IFNs. JAK inhibitors have shown promise in treating DM, particularly in refractory cases. However, more research is needed to fully understand their efficacy and safety profiles in IIMs. The review concludes by highlighting the importance of ongoing research in this area and the potential for new targeted therapies in treating IIMs.</p>","PeriodicalId":10193,"journal":{"name":"Clinical and Experimental Neuroimmunology","volume":"16 1","pages":"64-71"},"PeriodicalIF":0.0,"publicationDate":"2025-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143455840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ravulizumab in juvenile myasthenia gravis: An effective treatment in a 17-year-old girl Ravulizumab治疗青少年重症肌无力:对17岁女孩的有效治疗
Q4 Immunology and Microbiology Pub Date : 2025-01-19 DOI: 10.1111/cen3.12828
Domizia Vecchio, Amanda Papa, Giada Filisetti, Francesca Brustia, Cristoforo Comi, Roberto Cantello

Background

Ravulizumab, a monoclonal antibody against C5, is not currently approved for juvenile myasthenia gravis (MG).

Case Presentation

We are presenting a 14-year-old Moroccan girl diagnosed with antibody-positive generalized MG first treated with pyridostigmine 240 mg, prednisone 1 mg/kg/day, and thymectomy. Her clinical status remained unchanged (MG Foundation of America Clinical Classification: IIIa) with azathioprine 3 mg/kg, and steroids up to 2 mg/kg/day. She also required three rescue therapies over the subsequent 8 months, gained 10 kg, and had insomnia. We started compassionate ravulizumab treatment, as part of Alexion Pharmaceuticals expanded access program. At screening, the Myasthenia Gravis–Activities of Daily Living scale total score was 4, and Quantitative Myasthenia Gravis total scores were 13 (handgrip and forced vital capacity not performed). She continued her treatment every 8 weeks, and, at week 60, her Myasthenia Gravis–Activities of Daily Living scale total score was 0, and Quantitative Myasthenia Gravis total score was 1. This status was achieved despite an ongoing steroid tapering, that was possibly allowed using a rapidly-acting treatment. No significant infection or adverse effects were collected.

Conclusions

We are presenting the first case of juvenile MG treated with ravulizumab. Clinical assessment showed at week 60 an improvement of 12 points according to the Quantitative Myasthenia Gravis scoring system, and 3 points to the Myasthenia Gravis–Activities of Daily Living scale total score. This case report supports the efficacy and safety of ravulizumab in MG patients aged <18 years.

背景:Ravulizumab是一种抗C5的单克隆抗体,目前尚未被批准用于治疗青少年重症肌无力(MG)。我们报告了一名14岁的摩洛哥女孩,被诊断为抗体阳性的全身性MG,首先接受吡地斯的明240 MG,强的松1 MG /kg/天和胸腺切除术治疗。她的临床状态保持不变(美国MG基金会临床分类:IIIa),硫唑嘌呤3mg /kg,类固醇高达2mg /kg/天。在随后的8个月里,她还接受了三次抢救治疗,体重增加了10公斤,并出现失眠。我们开始了富有同情心的ravulizumab治疗,作为Alexion制药公司扩大准入计划的一部分。筛查时,重症肌无力-日常生活活动量表总分为4分,定量重症肌无力总分为13分(不进行握力和用力肺活量)。每8周继续治疗一次,第60周重症肌无力-日常生活活动量表总分为0分,定量重症肌无力总分为1分。尽管正在进行类固醇减量治疗,但仍达到了这一状态,这可能允许使用速效治疗。未发现明显感染或不良反应。结论:我们报告了第一例用ravulizumab治疗的青少年MG。临床评估显示,第60周重症肌无力定量评分系统评分提高12分,重症肌无力-日常生活活动量表总分提高3分。本病例报告支持ravulizumab治疗18岁MG患者的有效性和安全性。
{"title":"Ravulizumab in juvenile myasthenia gravis: An effective treatment in a 17-year-old girl","authors":"Domizia Vecchio,&nbsp;Amanda Papa,&nbsp;Giada Filisetti,&nbsp;Francesca Brustia,&nbsp;Cristoforo Comi,&nbsp;Roberto Cantello","doi":"10.1111/cen3.12828","DOIUrl":"https://doi.org/10.1111/cen3.12828","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Ravulizumab, a monoclonal antibody against C5, is not currently approved for juvenile myasthenia gravis (MG).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case Presentation</h3>\u0000 \u0000 <p>We are presenting a 14-year-old Moroccan girl diagnosed with antibody-positive generalized MG first treated with pyridostigmine 240 mg, prednisone 1 mg/kg/day, and thymectomy. Her clinical status remained unchanged (MG Foundation of America Clinical Classification: IIIa) with azathioprine 3 mg/kg, and steroids up to 2 mg/kg/day. She also required three rescue therapies over the subsequent 8 months, gained 10 kg, and had insomnia. We started compassionate ravulizumab treatment, as part of Alexion Pharmaceuticals expanded access program. At screening, the Myasthenia Gravis–Activities of Daily Living scale total score was 4, and Quantitative Myasthenia Gravis total scores were 13 (handgrip and forced vital capacity not performed). She continued her treatment every 8 weeks, and, at week 60, her Myasthenia Gravis–Activities of Daily Living scale total score was 0, and Quantitative Myasthenia Gravis total score was 1. This status was achieved despite an ongoing steroid tapering, that was possibly allowed using a rapidly-acting treatment. No significant infection or adverse effects were collected.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>We are presenting the first case of juvenile MG treated with ravulizumab. Clinical assessment showed at week 60 an improvement of 12 points according to the Quantitative Myasthenia Gravis scoring system, and 3 points to the Myasthenia Gravis–Activities of Daily Living scale total score. This case report supports the efficacy and safety of ravulizumab in MG patients aged &lt;18 years.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10193,"journal":{"name":"Clinical and Experimental Neuroimmunology","volume":"16 4","pages":"370-373"},"PeriodicalIF":0.0,"publicationDate":"2025-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145436003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical value of the Japanese version of patient-reported multiple sclerosis neuropsychological screening questionnaire 日本版多发性硬化症神经心理筛查问卷的临床价值
Q4 Immunology and Microbiology Pub Date : 2025-01-19 DOI: 10.1111/cen3.12829
Atsuya Muryoi, Michiko Nei, Juichi Fujimori, Ichiro Nakashima

Background

Neuropsychological abnormalities are common in patients with multiple sclerosis (MS); however, unlike motor and sensory deficits, their measurement in a clinical setting can be difficult.

Methods

We evaluated 80 patients with MS using the newly created Japanese version of a patient-report form of the Multiple Sclerosis Neuropsychological Questionnaire (MSNQ) and compared the results with those of processing speed tests (PST), namely, CogEval, and health-related quality of life (QOL). QOL was evaluated using the Medical Outcomes Study Short Form-36 Health Survey (SF-36).

Results

The partial correlation coefficient, after excluding the effect of disease duration, showed that the total MSNQ score was significantly correlated with PST (r = −0.2798, P = .0125), mental component summary (MCS) (r = −0.2913, P = .0092), and social role component summary (RCS) (r = −0.2591, P = .0211) in SF-36. Multiple linear regression analyses showed that physical component summary was significantly associated with age (P = .0158), EDSS (P = .0005), and CogEval raw score (P = .0029), whereas MCS was significantly associated with MSNQ (P = .0007). When patients with MS were divided into two groups using a median total MSNQ score threshold of 17, those with high MSNQ scores showed significantly higher EDSS scores (P = .0101), lower PST scores (P = .0426), and lower MCS scores in SF-36 (P = .0083).

Conclusion

The Japanese version of the patient-reported MSNQ can be useful in identifying patients with decreased mental QOL, which might be more difficult than to capture physical QOL.

神经心理异常在多发性硬化症(MS)患者中很常见;然而,与运动和感觉缺陷不同,它们在临床环境中的测量可能很困难。方法采用新制作的日文版多发性硬化症神经心理问卷(MSNQ)对80例多发性硬化症患者进行评估,并与处理速度测试(PST),即认知评价(CogEval)和健康相关生活质量(QOL)的结果进行比较。使用医疗结果研究短表-36健康调查(SF-36)评估生活质量。结果在排除病程影响后,偏相关系数显示MSNQ总分与PST呈显著相关(r = - 0.2798, P =。0125),心理成分总结(MCS) (r = - 0.2913, P =。0092),社会角色成分总结(RCS) (r = - 0.2591, P =。0211)在SF-36。多元线性回归分析显示,身体成分汇总与年龄显著相关(P =。0158), edss (p =。和CogEval原始评分(P = 0.0001)。0029),而MCS与MSNQ显著相关(P = .0007)。将MS患者分为两组,MSNQ评分中位数总阈值为17,MSNQ评分高的患者EDSS评分显著高于对照组(P =。0101),较低的PST评分(P =。0426), SF-36的MCS评分较低(P = 0.0083)。结论日文患者自述MSNQ可用于识别精神生活质量下降的患者,而精神生活质量下降可能比生理生活质量下降更困难。
{"title":"Clinical value of the Japanese version of patient-reported multiple sclerosis neuropsychological screening questionnaire","authors":"Atsuya Muryoi,&nbsp;Michiko Nei,&nbsp;Juichi Fujimori,&nbsp;Ichiro Nakashima","doi":"10.1111/cen3.12829","DOIUrl":"https://doi.org/10.1111/cen3.12829","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Neuropsychological abnormalities are common in patients with multiple sclerosis (MS); however, unlike motor and sensory deficits, their measurement in a clinical setting can be difficult.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We evaluated 80 patients with MS using the newly created Japanese version of a patient-report form of the Multiple Sclerosis Neuropsychological Questionnaire (MSNQ) and compared the results with those of processing speed tests (PST), namely, CogEval, and health-related quality of life (QOL). QOL was evaluated using the Medical Outcomes Study Short Form-36 Health Survey (SF-36).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The partial correlation coefficient, after excluding the effect of disease duration, showed that the total MSNQ score was significantly correlated with PST (r = −0.2798, <i>P =</i> .0125), mental component summary (MCS) (r = −0.2913, <i>P =</i> .0092), and social role component summary (RCS) (r = −0.2591, <i>P =</i> .0211) in SF-36. Multiple linear regression analyses showed that physical component summary was significantly associated with age (<i>P =</i> .0158), EDSS (<i>P =</i> .0005), and CogEval raw score (<i>P =</i> .0029), whereas MCS was significantly associated with MSNQ (<i>P =</i> .0007). When patients with MS were divided into two groups using a median total MSNQ score threshold of 17, those with high MSNQ scores showed significantly higher EDSS scores (<i>P =</i> .0101), lower PST scores (<i>P =</i> .0426), and lower MCS scores in SF-36 (<i>P =</i> .0083).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The Japanese version of the patient-reported MSNQ can be useful in identifying patients with decreased mental QOL, which might be more difficult than to capture physical QOL.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10193,"journal":{"name":"Clinical and Experimental Neuroimmunology","volume":"16 4","pages":"332-340"},"PeriodicalIF":0.0,"publicationDate":"2025-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145436002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Aberrant expression of long noncoding RNAs regulates inflammasome activation via oxidative stress: A novel mechanism for neuroinflammation and neurodegeneration in Parkinson's disease 长链非编码rna的异常表达通过氧化应激调节炎性体的激活:帕金森病神经炎症和神经变性的新机制
Q4 Immunology and Microbiology Pub Date : 2025-01-17 DOI: 10.1111/cen3.12830
Irene Mary Praveen, Latchoumycandane Calivarathan

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta, leading to hallmark motor symptoms such as bradykinesia, tremors, and rigidity. Emerging evidence suggests that the dysregulation or aberrant expression of long noncoding RNAs (lncRNAs) plays a critical role in the pathogenesis of PD by activating the inflammasome, either directly or via oxidative stress. Aberrant lncRNA expression has been linked to alterations in genes related to oxidative stress, causing an imbalance between reactive oxygen species (ROS) and antioxidant defenses. This imbalance contributes to mitochondrial dysfunction and neuronal damage. The NLRP3 inflammasome is a multiprotein complex comprising a sensor protein (eg, NLRP3), an adaptor protein (ASC), and an effector protein (caspase-1). Its activation involves priming via NF-κB signaling and is triggered by ROS, mitochondrial dysfunction, death-associated molecular patterns, or extracellular ATP. Once activated, the inflammasome promotes the cleavage and maturation of the proinflammatory cytokines IL-1β and IL-18, amplifying neuroinflammation and leading to neurodegeneration in PD. Crosstalk between dysregulated lncRNAs, ROS production, and inflammasome activation creates a vicious cycle of neuroinflammation and neurodegeneration, exacerbating PD progression. This review explores the molecular mechanisms linking lncRNA dysregulation to inflammasome activation in PD, either directly or through oxidative stress. It also highlights key lncRNAs involved in these processes. Furthermore, potential therapeutic strategies targeting these pathways, such as antioxidants, lncRNA modulators, and inflammasome inhibitors, offer promising avenues to mitigate neuroinflammation and slow neurodegeneration in PD.

帕金森病(PD)是一种进行性神经退行性疾病,其特征是黑质致密部多巴胺能神经元的丧失,导致运动迟缓、震颤和僵硬等标志性运动症状。新出现的证据表明,长链非编码rna (lncRNAs)的失调或异常表达通过直接或通过氧化应激激活炎性体,在PD的发病机制中起着关键作用。lncRNA的异常表达与氧化应激相关基因的改变有关,导致活性氧(ROS)和抗氧化防御之间的失衡。这种不平衡导致线粒体功能障碍和神经元损伤。NLRP3炎症小体是一种多蛋白复合物,包括传感器蛋白(如NLRP3)、接头蛋白(ASC)和效应蛋白(caspase-1)。它的激活包括NF-κB信号的启动,并由ROS、线粒体功能障碍、死亡相关分子模式或细胞外ATP触发。一旦被激活,炎症小体促进促炎细胞因子IL-1β和IL-18的裂解和成熟,放大神经炎症并导致PD的神经退行性变。失调的lncrna、ROS产生和炎性体激活之间的串扰形成了神经炎症和神经退行性变的恶性循环,加剧了PD的进展。这篇综述探讨了PD中lncRNA失调与炎症小体激活的分子机制,无论是直接的还是通过氧化应激。它还强调了参与这些过程的关键lncrna。此外,针对这些通路的潜在治疗策略,如抗氧化剂、lncRNA调节剂和炎性体抑制剂,为减轻PD患者的神经炎症和减缓神经退行性变提供了有希望的途径。
{"title":"Aberrant expression of long noncoding RNAs regulates inflammasome activation via oxidative stress: A novel mechanism for neuroinflammation and neurodegeneration in Parkinson's disease","authors":"Irene Mary Praveen,&nbsp;Latchoumycandane Calivarathan","doi":"10.1111/cen3.12830","DOIUrl":"https://doi.org/10.1111/cen3.12830","url":null,"abstract":"<p>Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta, leading to hallmark motor symptoms such as bradykinesia, tremors, and rigidity. Emerging evidence suggests that the dysregulation or aberrant expression of long noncoding RNAs (lncRNAs) plays a critical role in the pathogenesis of PD by activating the inflammasome, either directly or via oxidative stress. Aberrant lncRNA expression has been linked to alterations in genes related to oxidative stress, causing an imbalance between reactive oxygen species (ROS) and antioxidant defenses. This imbalance contributes to mitochondrial dysfunction and neuronal damage. The NLRP3 inflammasome is a multiprotein complex comprising a sensor protein (eg, NLRP3), an adaptor protein (ASC), and an effector protein (caspase-1). Its activation involves priming via NF-κB signaling and is triggered by ROS, mitochondrial dysfunction, death-associated molecular patterns, or extracellular ATP. Once activated, the inflammasome promotes the cleavage and maturation of the proinflammatory cytokines IL-1β and IL-18, amplifying neuroinflammation and leading to neurodegeneration in PD. Crosstalk between dysregulated lncRNAs, ROS production, and inflammasome activation creates a vicious cycle of neuroinflammation and neurodegeneration, exacerbating PD progression. This review explores the molecular mechanisms linking lncRNA dysregulation to inflammasome activation in PD, either directly or through oxidative stress. It also highlights key lncRNAs involved in these processes. Furthermore, potential therapeutic strategies targeting these pathways, such as antioxidants, lncRNA modulators, and inflammasome inhibitors, offer promising avenues to mitigate neuroinflammation and slow neurodegeneration in PD.</p>","PeriodicalId":10193,"journal":{"name":"Clinical and Experimental Neuroimmunology","volume":"16 3","pages":"237-253"},"PeriodicalIF":0.0,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144782946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unmasking the muscle mysteries: Cutting-edge insights into inflammatory myopathies 揭开肌肉之谜:炎性肌病的前沿见解
Q4 Immunology and Microbiology Pub Date : 2025-01-08 DOI: 10.1111/cen3.12826
Satoshi Yamashita
{"title":"Unmasking the muscle mysteries: Cutting-edge insights into inflammatory myopathies","authors":"Satoshi Yamashita","doi":"10.1111/cen3.12826","DOIUrl":"https://doi.org/10.1111/cen3.12826","url":null,"abstract":"","PeriodicalId":10193,"journal":{"name":"Clinical and Experimental Neuroimmunology","volume":"16 1","pages":"42-43"},"PeriodicalIF":0.0,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143455743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Update on pathology of inflammatory myopathy 炎性肌病的病理进展
Q4 Immunology and Microbiology Pub Date : 2025-01-07 DOI: 10.1111/cen3.12824
Akinori Uruha, Satoko Uruha

Inflammatory myopathy is classified into primary autoimmune myositis and secondary myositis due to various factors, such as drugs and autoimmune connective tissue diseases. Autoimmune myositis mainly consists of dermatomyositis, antisynthetase syndrome-associated myositis, immune-mediated necrotizing myopathy, and inclusion body myositis. This review aims to provide insights into muscle pathology for clinical practice and an understanding of pathophysiology in inflammatory myopathy by summarizing current knowledge about the pathology of each subform of autoimmune myositis and some secondary myositis. Dermatomyositis is associated with type I interferon upregulation. Expression of myxovirus resistance protein A (a type I interferon-induced protein) in myofibers is utilized as a sensitive diagnostic marker. Antisynthetase syndrome-associated myositis is morphologically characterized by perifascicular necrosis. A recent study suggests the presence of a characteristic immunological micromilieu suitable for plasma cells in the skeletal muscle tissue. Immune-mediated necrotizing myopathy features an active necrotic and regenerating process. In inclusion body myositis, inflammatory cellular infiltration and rimmed vacuoles reflecting autophagy disruption are observed. The lymphocytes invading myofibers are composed of a highly differentiated T-cell population, which is considered a potential therapeutic target.

炎症性肌病可分为原发性自身免疫性肌炎和继发性肌炎,受药物、自身免疫性结缔组织疾病等多种因素的影响。自身免疫性肌炎主要包括皮肌炎、抗合成酶综合征相关性肌炎、免疫介导的坏死性肌病和包涵体肌炎。本综述旨在通过总结目前对自身免疫性肌炎和一些继发性肌炎各亚型病理的了解,为临床实践提供肌肉病理学的见解,并了解炎症性肌病的病理生理学。皮肌炎与I型干扰素上调有关。黏液病毒抵抗蛋白A(一种I型干扰素诱导蛋白)在肌纤维中的表达被用作敏感的诊断标记。抗合成酶综合征相关性肌炎在形态学上以筋膜周围坏死为特征。最近的一项研究表明,骨骼肌组织中存在一种适合浆细胞的特征性免疫微环境。免疫介导的坏死性肌病具有活跃的坏死和再生过程。包涵体肌炎可见炎性细胞浸润和反映自噬破坏的边缘空泡。侵袭肌纤维的淋巴细胞由高度分化的t细胞群组成,被认为是潜在的治疗靶点。
{"title":"Update on pathology of inflammatory myopathy","authors":"Akinori Uruha,&nbsp;Satoko Uruha","doi":"10.1111/cen3.12824","DOIUrl":"https://doi.org/10.1111/cen3.12824","url":null,"abstract":"<p>Inflammatory myopathy is classified into primary autoimmune myositis and secondary myositis due to various factors, such as drugs and autoimmune connective tissue diseases. Autoimmune myositis mainly consists of dermatomyositis, antisynthetase syndrome-associated myositis, immune-mediated necrotizing myopathy, and inclusion body myositis. This review aims to provide insights into muscle pathology for clinical practice and an understanding of pathophysiology in inflammatory myopathy by summarizing current knowledge about the pathology of each subform of autoimmune myositis and some secondary myositis. Dermatomyositis is associated with type I interferon upregulation. Expression of myxovirus resistance protein A (a type I interferon-induced protein) in myofibers is utilized as a sensitive diagnostic marker. Antisynthetase syndrome-associated myositis is morphologically characterized by perifascicular necrosis. A recent study suggests the presence of a characteristic immunological micromilieu suitable for plasma cells in the skeletal muscle tissue. Immune-mediated necrotizing myopathy features an active necrotic and regenerating process. In inclusion body myositis, inflammatory cellular infiltration and rimmed vacuoles reflecting autophagy disruption are observed. The lymphocytes invading myofibers are composed of a highly differentiated T-cell population, which is considered a potential therapeutic target.</p>","PeriodicalId":10193,"journal":{"name":"Clinical and Experimental Neuroimmunology","volume":"16 1","pages":"55-63"},"PeriodicalIF":0.0,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143455935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Two cases illustrating different neurological aspects of HIV-escape syndrome 两个病例说明了hiv逃逸综合征的不同神经方面
Q4 Immunology and Microbiology Pub Date : 2025-01-01 DOI: 10.1111/cen3.12825
Merve Aktan Suzgun, Rümeysa Unkun, Osman Kizilkilic, Birgul Mete, Fehmi Tabak, Ugur Uygunoglu

Background

HIV escape syndrome is characterized by high viral load in the central nervous system despite having a low serum viral load and typically detected after the initiation of antiretroviral therapy during the course of HIV infection. The aim of this report was to reveal different aspects of the neurological involvement of HIV-escape syndrome and to define the discrete phenotypes of HIV-escape syndrome characterized by predominant inflammation or HIV-associated neurocognitive disorder.

Case Presentation

Two cases are presented, both were followed collaboratively by neurology and infectious diseases clinics, where the ones in which neurologic complaints associated with HIV-positivity aggravated by development of HIV-escape syndrome. The first case, investigated for progressive vision loss, represented the inflammatory course of HIV-escape with vasculitic involvement on imaging, positive serum anti-NMDA-R antibody, and good response to immunotherapy. On the other hand, the second case, who presented with progressive confusion and difficulty in walking, exemplifies the HIV-associated neurocognitive disorder with parenchymal atrophy, no evidence of inflammation, and benefit only from antiretroviral treatment modifications.

Conclusion

With regard to the discussions detailed herein, identifying HIV-escape syndrome as a balance of viral colonization and antiviral defense dynamics rather than a homogeneous clinical entity will broaden the clinical approaches needed. It should be particularly borne in mind that the initial neurological status may be exacerbated if HIV-escape syndrome develops.

HIV逃逸综合征的特点是中枢神经系统病毒载量高,尽管血清病毒载量低,通常在HIV感染过程中开始抗逆转录病毒治疗后检测到。本报告的目的是揭示hiv -逃逸综合征的神经系统参与的不同方面,并定义以主要炎症或hiv相关神经认知障碍为特征的hiv -逃逸综合征的离散表型。本文介绍了两个病例,这两个病例都是由神经病学和传染病诊所合作进行的,其中与艾滋病毒阳性相关的神经系统疾病因艾滋病毒逃逸综合征的发展而加重。第一例为进行性视力丧失,表现为hiv逃逸的炎症过程,影像学表现为血管受累,血清抗nmda - r抗体阳性,对免疫治疗反应良好。另一方面,第二例患者表现为进行性意识模糊和行走困难,体现了hiv相关的神经认知障碍伴实质萎缩,无炎症迹象,只能从抗逆转录病毒治疗中获益。关于本文的详细讨论,将hiv逃逸综合征确定为病毒定殖和抗病毒防御动力学的平衡,而不是单一的临床实体,将拓宽所需的临床方法。应该特别记住,如果艾滋病毒逃逸综合症发展,最初的神经系统状况可能会恶化。
{"title":"Two cases illustrating different neurological aspects of HIV-escape syndrome","authors":"Merve Aktan Suzgun,&nbsp;Rümeysa Unkun,&nbsp;Osman Kizilkilic,&nbsp;Birgul Mete,&nbsp;Fehmi Tabak,&nbsp;Ugur Uygunoglu","doi":"10.1111/cen3.12825","DOIUrl":"https://doi.org/10.1111/cen3.12825","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>HIV escape syndrome is characterized by high viral load in the central nervous system despite having a low serum viral load and typically detected after the initiation of antiretroviral therapy during the course of HIV infection. The aim of this report was to reveal different aspects of the neurological involvement of HIV-escape syndrome and to define the discrete phenotypes of HIV-escape syndrome characterized by predominant inflammation or HIV-associated neurocognitive disorder.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case Presentation</h3>\u0000 \u0000 <p>Two cases are presented, both were followed collaboratively by neurology and infectious diseases clinics, where the ones in which neurologic complaints associated with HIV-positivity aggravated by development of HIV-escape syndrome. The first case, investigated for progressive vision loss, represented the inflammatory course of HIV-escape with vasculitic involvement on imaging, positive serum anti-NMDA-R antibody, and good response to immunotherapy. On the other hand, the second case, who presented with progressive confusion and difficulty in walking, exemplifies the HIV-associated neurocognitive disorder with parenchymal atrophy, no evidence of inflammation, and benefit only from antiretroviral treatment modifications.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>With regard to the discussions detailed herein, identifying HIV-escape syndrome as a balance of viral colonization and antiviral defense dynamics rather than a homogeneous clinical entity will broaden the clinical approaches needed. It should be particularly borne in mind that the initial neurological status may be exacerbated if HIV-escape syndrome develops.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10193,"journal":{"name":"Clinical and Experimental Neuroimmunology","volume":"16 3","pages":"282-287"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144782646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Can specific dietary patterns and lifestyle habits influence the progression of intracranial aneurysm lesions? 特定的饮食模式和生活习惯会影响颅内动脉瘤病变的进展吗?
Q4 Immunology and Microbiology Pub Date : 2024-12-26 DOI: 10.1111/cen3.12801
Vivig Shantha Kumar, Nerella Resheek, Vignarth Shantha Kumar, Ruthvik Thaghalli Sunil Kumar

The progression of intracranial aneurysm lesions involves complex mechanisms influenced by various factors, including inflammation, oxidative stress and endothelial dysfunction. This comprehensive review delves into the intricate interplay between specific dietary patterns and the progression of intracranial aneurysm lesions. Understanding the impact of these dietary factors on inflammation, oxidative stress and endothelial dysfunction offers valuable insights into noninvasive strategies for managing intracranial aneurysm progression, addressing a critical gap in current therapeutic approaches.

颅内动脉瘤病变的发展机制复杂,受多种因素影响,包括炎症、氧化应激和内皮功能障碍。这篇综合综述深入研究了特定饮食模式与颅内动脉瘤病变进展之间复杂的相互作用。了解这些饮食因素对炎症、氧化应激和内皮功能障碍的影响,为管理颅内动脉瘤进展的无创策略提供了有价值的见解,解决了当前治疗方法的关键空白。
{"title":"Can specific dietary patterns and lifestyle habits influence the progression of intracranial aneurysm lesions?","authors":"Vivig Shantha Kumar,&nbsp;Nerella Resheek,&nbsp;Vignarth Shantha Kumar,&nbsp;Ruthvik Thaghalli Sunil Kumar","doi":"10.1111/cen3.12801","DOIUrl":"https://doi.org/10.1111/cen3.12801","url":null,"abstract":"<p>The progression of intracranial aneurysm lesions involves complex mechanisms influenced by various factors, including inflammation, oxidative stress and endothelial dysfunction. This comprehensive review delves into the intricate interplay between specific dietary patterns and the progression of intracranial aneurysm lesions. Understanding the impact of these dietary factors on inflammation, oxidative stress and endothelial dysfunction offers valuable insights into noninvasive strategies for managing intracranial aneurysm progression, addressing a critical gap in current therapeutic approaches.</p>","PeriodicalId":10193,"journal":{"name":"Clinical and Experimental Neuroimmunology","volume":"16 3","pages":"265-281"},"PeriodicalIF":0.0,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144782842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Amyloid-related imaging abnormalities in a woman with apolipoprotein E ε4 homozygotes treated with lecanemab for Alzheimer's disease 用lecanemab治疗阿尔茨海默病的载脂蛋白E ε4纯合子女性的淀粉样蛋白相关影像学异常
Q4 Immunology and Microbiology Pub Date : 2024-12-09 DOI: 10.1111/cen3.12821
Moeko Noguchi-Shinohara, Junji Komatsu, Kenjiro Ono

Background

Lecanemab (Leqembi®) is an anti-amyloid monoclonal antibody used for the treatment of Alzheimer's disease (AD). However, side effects may occur with lecanemab, including amyloid-related imaging abnormalities (ARIA), especially in patients with apolipoprotein E ε4 (APOE4) homozygous.

Case Presentation

A 69-year-old woman had a 2-year history of worsening memory symptoms and was diagnosed with mild cognitive impairment due to AD. Because she carries two copies of the E4 allele of APOE, her doctor did not recommend lecanemab treatment. However, she strongly desired lecanemab treatment and received four infusions of lecanemab. She had no symptoms or neurological abnormalities, but a head MRI before the fifth infusion showed moderate radiographic ARIA; therefore, she was admitted and treated with steroids. One month later, a head MRI showed the ARIA had disappeared.

Conclusion

The indications of lecanemab treatment for patients with APOE4 homozygous must be carefully considered due to the higher risk of ARIA.

leanemab (Leqembi®)是一种用于治疗阿尔茨海默病(AD)的抗淀粉样蛋白单克隆抗体。然而,lecanemab可能会出现副作用,包括淀粉样蛋白相关成像异常(ARIA),特别是载脂蛋白E ε4 (APOE4)纯合子患者。病例介绍一名69岁女性,有2年的记忆症状恶化史,被诊断为AD引起的轻度认知障碍。因为她携带了两个APOE的E4等位基因,她的医生不建议她使用莱卡耐单抗治疗。然而,她强烈希望接受莱卡耐单抗治疗,并接受了四次莱卡耐单抗输注。她没有症状或神经系统异常,但在第五次输注前的头部MRI显示中度放射学ARIA;因此,她入院并接受类固醇治疗。一个月后,头部核磁共振显示ARIA消失了。结论APOE4纯合子患者发生ARIA的风险较高,应慎重选择莱卡耐单抗治疗的适应症。
{"title":"Amyloid-related imaging abnormalities in a woman with apolipoprotein E ε4 homozygotes treated with lecanemab for Alzheimer's disease","authors":"Moeko Noguchi-Shinohara,&nbsp;Junji Komatsu,&nbsp;Kenjiro Ono","doi":"10.1111/cen3.12821","DOIUrl":"https://doi.org/10.1111/cen3.12821","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Lecanemab (Leqembi®) is an anti-amyloid monoclonal antibody used for the treatment of Alzheimer's disease (AD). However, side effects may occur with lecanemab, including amyloid-related imaging abnormalities (ARIA), especially in patients with apolipoprotein E ε4 (<i>APOE4</i>) homozygous.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Case Presentation</h3>\u0000 \u0000 <p>A 69-year-old woman had a 2-year history of worsening memory symptoms and was diagnosed with mild cognitive impairment due to AD. Because she carries two copies of the E4 allele of <i>APOE</i>, her doctor did not recommend lecanemab treatment. However, she strongly desired lecanemab treatment and received four infusions of lecanemab. She had no symptoms or neurological abnormalities, but a head MRI before the fifth infusion showed moderate radiographic ARIA; therefore, she was admitted and treated with steroids. One month later, a head MRI showed the ARIA had disappeared.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The indications of lecanemab treatment for patients with <i>APOE4</i> homozygous must be carefully considered due to the higher risk of ARIA.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10193,"journal":{"name":"Clinical and Experimental Neuroimmunology","volume":"16 3","pages":"254-257"},"PeriodicalIF":0.0,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144782489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Clinical and Experimental Neuroimmunology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1